Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Apollo decides against bid for Costa Coffee - report

(Sharecast News) - A small number of suitors have reportedly served up initial bids for Costa Coffee as owner Coca-Cola prepares to retain ownership of the brand's ready-to-drink portfolio, while Apollo Global Management was said to have changed its mind about submitting a bid. According to Sky News, Coca-Cola and its advisers set a deadline last week for indicative offers for Costa.

City sources told Sky on Monday that investment giant Apollo, which had expressed an interest in the business, decided not to submit an offer.

Other reported bidders include TDR Capital, the owner of Asda, although banking insiders said there had been a small number of proposals than expected.

One suggested that the value placed on Costa could be as low as £1.5bn, well under half the £3.9bn paid by Coca-Cola in 2021.

Sky said it was unclear whether Coca-Cola would be prepared to offload the business at that price.

Coca-Cola is said to have told suitors that it would retain control of the ready-to-drink Costa range sold in supermarkets and other grocery outlets.

Sky News revealed last month that Coca-Cola was exploring a disposal of Costa, which trades from more than 2,000 stores in the UK and well over 3,000 globally.

It has been reported to have a global workforce numbering 35,000, although Coca-Cola has not responded to any questions from Sky News about the Costa business or sale process.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.